CDC-RFA-OE20-20010301SUPP23: CDC-RFA-OE20-2001: Enhancing Public Health Laboratory Capabilities and Increasing Capacity
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - CSELS notices from 2023.
Centers for Disease Control - CSELS offered grants of up to $3.0 million (at least $100,000) to the applicants described in the notice. It expected to make one award worth $2.0 million in total. Applications closed on March 23, 2023.
From the official notice on Grants.gov, last changed January 23, 2023. Checked November 7, 2026.
- Award ceiling$3.0 million
- Award floor$100,000
- Total funding$2.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | January 22, 2023 |
|---|---|
| Deadline | March 23, 2023 |
| Archived by Grants.gov | May 23, 2023 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
This supplemental funding opportunity announcement is a single-source eligibility. The only applicant eligible to apply is the Association for Public Health Laboratories (APHL) because this NOFO is a single-source award and due to specialized skills and abilities to enhance the capacity of public health laboratories (PHLs).
Is this a realistic fit?
- Past CDC Partnership: Strengthening Public Health Laboratories awards averaged $65.5 million; this notice allows up to $3.0 million per award.
- Most of the program's money (100% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
State, local, and territorial public health laboratories (PHLs) play an indispensable role in protecting the health of Americans from new, emerging, and existing health threats by conducting laboratory testing and providing other science-based services. The work of PHL systems is interdigitate with other aspects of public health work, including epidemiology. Public health professionals and policy makers use actionable information from PHLs daily to identify and prioritize these population health threats, and to develop and implement effective interventions. In order to fulfill their critical public health mission, PHLs must be capable of and effective at detecting and responding to a myriad of threats across a broad and expanding spectrum of health domains, including infectious and chronic diseases, chemical and radiological exposure, newborn disease, foodborne and waterborne diseases, public health emergencies, such as COVID-19, and others in the United States and globally. Despite their critical functions, PHLs face serious challenges in developing the capacities and capabilities to perform their role. Among these challenges are the rapid emergence of new disease threats, the accelerating evolution in technology and testing methods, and the growing complexities in developing broad interoperability and improving data exchange between laboratory data systems, health information systems, and other data systems. In addition, ensuring safe laboratory practices with existing and new technologies, and enhancing the infrastructure and capacity of the public health laboratory workforce continue to be pressing priorities for PHLs. Furthermore, PHLs often face persistent fiscal problems, workforce reductions, and other problems that threaten their development of needed capabilities to address public health issues, and, in some cases, their ability to perform important testing services. PHLs need to address these ongoing challenges to serve as effective partners, to integrate into the larger, national public health system. The overarching purpose of this cooperative agreement is to improve the effectiveness of PHLs, individually and as components of a national system, to improve public health in the United States and globally. CDC is taking a multi-pronged approach to provide needed COVID-19 funding to PHLs.
Who has won CDC Partnership: Strengthening Public Health Laboratories grants before
From fiscal 2021 to 2025, CDC Partnership: Strengthening Public Health Laboratories (93.322) awarded $458 million across 7 grant awards, an average of $65.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Association of Public Health Laboratories, Inc. (the) | Maryland | 2 | $460 million |
| American Society for Clinical Pathology | Illinois | 1 | $1.1 million |
| University of Maryland, Baltimore | Maryland | 1 | $687,186 |
| City of New York | New York | 1 | $685,095 |
| American Society for Clinical Laboratory Science | Virginia | 1 | $621,500 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-OE20-20010301SUPP23 still open?
No. It closed on March 23, 2023.
Who can apply for CDC-RFA-OE20-2001: Enhancing Public Health Laboratory Capabilities and Increasing Capacity?
Centers for Disease Control - CSELS accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for CDC-RFA-OE20-2001: Enhancing Public Health Laboratory Capabilities and Increasing Capacity?
Closed March 23, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $3.0 million each. About $2.0 million in total for one award.
Who has won CDC Partnership: Strengthening Public Health Laboratories grants before?
The largest recipients over five fiscal years were Association of Public Health Laboratories, Inc. (the), American Society for Clinical Pathology, University of Maryland, Baltimore. The program made 7 awards worth $458 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)